Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 10/14/14  and contains information from public web pages and contributions from the ZoomInfo community.

Mr. Nikolaj Sørensen

Wrong Nikolaj Sørensen?

President and Chief Executive Off...

Orexo AB
Virdings Alle 32 A
Uppsala , 751 05

Company Description: Orexo AB is a Sweden-based company, active within the pharmaceutical industry. The Company focuses primarily on the development of new, patented drugs by combining...   more

Employment History


  • M.Sc.
  • Master of Science , Business and Economics
93 Total References
Web References
said Nikolaj Sørensen, CEO ..., 14 Oct 2014 [cached]
said Nikolaj Sørensen, CEO and President of Orexo AB.
Nikolaj Sørensen, CEO and President of Orexo AB, noted "Many patients suffering from opioid dependence have difficulties in finding waivered physicians, with an expanded label Orexo can take an active role to encourage and educate the waivered, but not active, prescribers in initiation of treatment and improve access to treatment for patient suffering from opioid dependence."
Orexo Annual Report 2012, 12 Oct 2014 [cached]
Nikolaj Sørensen President
Our audit report was submitted on March 19, 2013.
Orexo: Orexo ..., 5 Feb 2013 [cached]
Orexo: Orexo strengthens the commercial leadership structure and appoints Nikolaj Sørensen as new CEO and Martin Nicklasson as Executive Chairman
Nikolaj Sørensen, currently Chief Commercial Officer of Orexo, will be promoted to CEO of the company and Martin Nicklasson, currently Chairman of the Board, will be appointed Executive Chairman, both effective as of today.
Nikolaj Sørensen will succeed Anders Lundström, who will step down as CEO of the company after successful two year tenure.
Nikolaj Sørensen has been central to this process. In order to enhance the company focus on this opportunity, the Board has decided that operations, which today primarily are directed towards support of Zubsolv, should be firmly anchored under Nikolaj Sørensen's leadership.
Nikolaj Sørensen commented "I am excited and honored to be appointed CEO of Orexo, and I look forward to closely working with Martin Nicklasson to secure the optimal commercialization for Zubsolv and Abstral in the United States."
I'm looking forward to working with Nikolaj Sørensen and the leadership team towards this common goal."
Nikolaj Sørensen joined Orexo AB in October 2011 and has focused the company's activities towards the business opportunities within the US opioid addiction market.
Nikolaj Sørensen, Chief Commercial Officer Tel: +46-703-50 78 88, Email:
Press releases - Orexo, 16 Sept 2011 [cached]
Orexo strengthens its commercial knowhow and appoints Nikolaj Sørensen as Chief Commercial Officer
Uppsala, Sweden, September 16, 2011 - Orexo AB (STO: ORX) appoints Nikolaj Sørensen as Chief Commercial Officer effective October 1, 2011. Nikolaj has extensive experience of the pharmaceutical industry and will be responsible for Orexo's commercial operations as well as development of the company's commercial strategies. His international commercial experience is a key asset in Orexo's goal to develop, market and sell proprietary products. Nikolaj will be reporting to the CEO and will be part of the company's executive management team.
Nikolaj Sørensen has a Master of Science in Business and Economics and previously worked at Pfizer where he was i.a. Director and Brand Team Leader for Pfizer's leading pain treatment product in Europe and Canada. At Pfizer, Nikolaj also worked as Head of Business Development and Director of Strategic Planning, acted as Business Area Director for primary care products, and as Managing Director and Chairman of the board for Pfizer AB. In addition, Nikolaj has been a member of the Board of the Swedish Pharmaceutical Industry Association (LIF) for the past few years.
Prior to working at Pfizer, Nikolaj was a consultant at Boston Consulting Group (BCG), focusing on life science and among other he was the Project Leader for the merger of Pfizer and Pharmacia in the Nordic region.
"Orexo is an exciting company that I have followed for several years. The company has a very interesting product portfolio that provides a solid foundation for a commercial organization. I look forward to developing and executing Orexo's strategy for sales and marketing of the company's own products," said Nikolaj Sørensen.
"Orexo has had a strong focus on commercial development since 2010 and we are particularly pleased that we have succeeded in recruiting Nikolaj Sørensen to be in charge of commercial operations.
"I am very happy to welcome Nikolaj to Orexo's executive management team."
Press release - Orexo strengthens its commercial knowhow and appoints Nikolaj Sørensen as CCO
Orexo Annual Report 2012, 12 Oct 2014 [cached]
1. Nikolaj Sørensen (b. 1972)
Other People with the name "Sørensen":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.